

**Baxter International Inc. (BAX:NYSE) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, and Recent Trends**

Company Report | 2024-08-12 | 135 pages | Quaintel Research

**AVAILABLE LICENSES:**

- Single User Price \$175.00
- Multi User Price \$195.00
- Enterprise User Price \$225.00

**Report description:**

Report Summary

Baxter International Inc. (BAX:NYSE) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, and Recent Trends Report is a comprehensive and easily accessible overview of Baxter International Inc.'s business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.

The report begins with in-depth information about Baxter International Inc. including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.

Next, the report assesses Baxter International Inc.'s strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company's operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of Baxter International Inc.'s overall strategic standing and supports informed decision-making and strategic planning.

The report also covers Baxter International Inc.'s financial analysis basis of latest income statement, balance sheet, and cash flow

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares Baxter International Inc.'s financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.

Finally, the report includes recent news and deal activities undertaken by Baxter International Inc. enhancing awareness of the company's business trends, growth perspectives, and more.

### Key Highlights

Baxter International Inc (Baxter) is a provider of a range of healthcare products. Its product and service offerings include dialysis in acute and chronic conditions, sterile intravenous solutions, generic injectable pharmaceuticals, parenteral nutrition therapies, infusion systems and devices, inhaled anesthetics and surgical hemostat and sealant products. The company's products find application in hospitals, rehabilitation centres, kidney dialysis centres, nursing homes, and patients at home. Baxter distributes its products through direct sales force and a network of independent distributors, drug wholesalers, specialty pharmacies and other alternative site providers. The company has operations in the Americas, the Middle East, Africa, Europe and Asia-Pacific. Baxter is headquartered in Deerfield, Illinois, the US.

### Baxter International Inc. in the News:-

- 17-Jul-2024 - Baxter to Host Second-Quarter 2024 Financial Results Conference Call for Investors
- 16-Jul-2024 - Baxter Declares Quarterly Dividend
- 10-Jul-2024 - Baxter Publishes Annual Corporate Responsibility Report, Highlighting Continued Focus on Creating Lasting Impact
- 29-May-2024 - New Cohort Study Data Shows Baxter's Expanded Hemodialysis - Known as HDx Therapy - is Associated with Approximately 25% Lower Mortality Rate for up to Four Years
- 15-May-2024 - Baxter Announces Mission and Logo for Proposed Kidney Care Company Vantive

### Scope

- Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
- Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
- Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company's future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
- Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
- Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.

### Reasons to Buy

- Comprehensive Understanding of the Baxter International Inc.'s internal and external factors through SWOT analysis, PESTLE analysis, Financial Analysis, and Competitors Benchmarking.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
- Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
- Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
- Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
- Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.

Additionally, available deep-dive analysis on the company Baxter International Inc.:

- Baxter International Inc. Value Chain Analysis
- Baxter International Inc. Porter's Five Forces Analysis
- Baxter International Inc. VRIO Analysis
- Baxter International Inc. BCG Analysis
- Baxter International Inc. Segmentation, Targeting and Positioning (STP) Analysis
- Baxter International Inc. Ansoff Matrix Analysis

### **Table of Contents:**

Table of Contents	
COMPANY EXECUTIVE SUMMARY	1
Table of Contents	2
Tables	6
Charts	7
Baxter International Inc. - Key Company Facts	8
Baxter International Inc. - Company Description	9
Baxter International Inc. - Top Executives	10
Baxter International Inc. - Top Executives Biographies	11
Baxter International Inc. - Head Office & Locations	14
Head Office - Country	14
Key Subsidiaries	15
Baxter International Inc. - Products and Services	17
Products	17
Services	19
Baxter International Inc. - Historic Events	20
Baxter International Inc. - Company's Management Discussion	22
Baxter International Inc. - Corporate Strategy	34
Baxter International Inc. - Business Description	38
Medical Products and Therapies	39
Healthcare Systems and Technologies	40
Pharmaceuticals	40
Kidney Care	41
Baxter International Inc. - ESG Spotlight	42
Environment	42
Social	43
Corporate Governance	44
Baxter International Inc. - SWOT Analysis	45

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Overview	45
Strengths	47
Weaknesses	50
Opportunities	52
Threats	55
Baxter International Inc. - PESTLE Analysis	57
Overview	57
Political Factors	59
Economic Factors	61
Social Factors	62
Technological Factors	63
Legal Factors	64
Environmental Factors	66
Baxter International Inc. - Financial Deep Dive	67
Share Price Trend - Aug-2023 to Aug-2024 (Average Share Closing Price)	67
Profit and Loss Statement	69
Summary of Profit and Loss Statement	69
Balance Sheet	71
Summary of Balance Sheet	71
Cash Flow Statement	73
Summary of Cash Flow Statement	73
Key Financial Ratio Analysis	75
Baxter International Inc. - Ratio Charts	76
Activity Ratio Charts	76
Growth Ratios Charts	77
Leverage Ratio Charts	78
Liquidity Ratio Charts	79
Profitability Ratio Charts	80
Competing Players	81
Snapshot of Competing Players	82
Abbott Laboratories	82
Key Company Facts	82
Company Description	82
Snapshot of Competing Players	84
Boston Scientific Corporation	84
Key Company Facts	84
Company Description	84
Snapshot of Competing Players	86
Fresenius Medical Care AG & Co KGaA	86
Key Company Facts	86
Company Description	86
Snapshot of Competing Players	88
Medtronic plc	88
Key Company Facts	88
Company Description	88
Snapshot of Competing Players	90
Stryker Corporation	90

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Key Company Facts	90
Company Description	90
Baxter International Inc. - In the News	92
17-Jul-2024 - Baxter to Host Second-Quarter 2024 Financial Results Conference Call for Investors	92
16-Jul-2024 - Baxter Declares Quarterly Dividend	93
10-Jul-2024 - Baxter Publishes Annual Corporate Responsibility Report, Highlighting Continued Focus on Creating Lasting Impact	93
29-May-2024 - New Cohort Study Data Shows Baxter's Expanded Hemodialysis - Known as HDx Therapy - is Associated with Approximately 25% Lower Mortality Rate for up to Four Years	94
15-May-2024 - Baxter Announces Mission and Logo for Proposed Kidney Care Company Vantive	95
11-Apr-2024 - Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.	96
01-Apr-2024 - Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy	98
27-Mar-2024 - Baxter to Host Annual Meeting of Stockholders in Virtual Format	100
29-Feb-2024 - Baxter to Present at Raymond James 45th Annual Institutional Investors Conference	102
27-Feb-2024 - Baxter Reinforces Guidance Regarding Urgent Medical Device Correction for Exactamix Pro Due to Software Overflow Error	102
14-Dec-2023 - Baxter Advances First Intravenous (IV) Bag Recycling Pilot for U.S. Hospitals	104
13-Dec-2023 - Baxter to Present at 42nd Annual J.P. Morgan Healthcare Conference	105
11-Dec-2023 - Baxter Publishes Task Force on Climate-related Financial Disclosures (TCFD) Report and is Named to Dow Jones Sustainability Index North America	106
29-Nov-2023 - Baxter Issues Urgent Medical Device Correction for Novum IQ Syringe Infusion Pump Due to Potential Impact of Downstream Occlusions on Infusion Volume	108
06-Nov-2023 - Baxter Highlights New Data at Kidney Week Indicating Sharesource is Associated with a 77% Lower Risk of Home Dialysis Technique Failure	110
16-Oct-2023 - Baxter Launches Digital Image Capture Capability for PanOptic Plus Ophthalmoscope	112
Baxter International Inc. - Key Deals	113
28-Nov-2023 - The Baxter International Foundation and UNICEF Partner to Expand Access to Safe Water and Sanitation in Egypt	113
08-May-2023 - Baxter Signs Definitive Agreement to Divest its BioPharma Solutions Business to Advent International and Warburg Pincus for \$4.25 Billion	115
01-Feb-2023 - Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure	118
06-Jan-2023 - Baxter Announces Strategic Actions to Enhance Operational Effectiveness, Accelerate Innovation for Patients and Drive Value for Shareholder	120
22-Sep-2022 - The Baxter International Foundation Announces \$3 Million In New Grants To Organizations Working To Advance Racial Justice	124
09-Mar-2022 - Digital Diagnostics and Baxter Announce New Partnership to Advance Diabetic Retinopathy Detection	126
13-Dec-2021 - Baxter Completes Acquisition of Hillrom, Creating ~\$15 Billion Global Medtech Leader	127
Appendix	129
Definitions	129
SWOT Analysis	129
PESTLE Analysis	129
Value Chain Analysis	129
ESG Spotlight	129
Financial Deep Dive	129
Financial Ratios	130

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Activity Ratios 130  
Growth Ratios 131  
Leverage Ratios 132  
Liquidity Ratios 133  
Market Ratios 134  
Profitability Ratios 134  
Research Methodology 135  
Disclaimer 136  
Contact Us 136

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Baxter International Inc. (BAX:NYSE) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, and Recent Trends**

Company Report | 2024-08-12 | 135 pages | Quaintel Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User Price	\$175.00
	Multi User Price	\$195.00
	Enterprise User Price	\$225.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-16"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Signature

An empty rectangular box with a thin black border, intended for a signature.